thiazolidines has been researched along with Diabetic Retinopathy in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (16.67) | 18.7374 |
| 1990's | 4 (33.33) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 2 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kakehashi, A; Kinoshita, N; Matsumoto, T; Ota, A; Shimmura, M; Takano, H; Tanaka, Y; Toyoda, F; Tsuji, J | 1 |
| Atsumi, Y; Baba, M; Hotta, N; Kawamori, R; Kishikawa, H; Nakamura, J; Oikawa, S; Shigeta, Y; Yamada, N; Yasuda, H | 1 |
| Fukuda, M; Hotta, N; Kawamori, R; Shigeta, Y | 1 |
| Kawakami, M; Kuroki, M | 1 |
| Inoue, M; Ishida, S; Izumi-Nagai, K; Koto, T; Nagai, N; Oike, Y; Ozawa, Y; Satofuka, S; Tsubota, K; Umezawa, K; Yamashiro, K | 1 |
| Aono, T; Fujita, T; Hamada, M; Hayakawa, N; Hayashi, R; Itoh, M; Kakizawa, H; Makino, M; Nagasaka, A; Nagata, M; Shinohara, R; Uchimura, K | 1 |
| Akagi, Y; Kasahara, T; Kinoshita, S; Kobayashi, T; Kubo, E; Mori, K; Takahashi, Y; Yokoi, N; Yonezawa, H | 1 |
| Hamada, Y; Horiuchi, S; Hotta, N; Kasuya, Y; Kato, K; Komori, T; Nagai, R; Nakamura, J; Naruse, K | 1 |
| Hotta, N; Sakamoto, N | 1 |
| Hotta, N; Sakakibara, F; Sakamoto, N | 1 |
| Harada, T; Hotta, N; Kakuta, H; Kojima, K; Matsubara, H; Mizuno, K; Sakamoto, N; Suzuki, M | 1 |
| Kador, PF; Kinoshita, JH; Sharpless, NE | 1 |
2 review(s) available for thiazolidines and Diabetic Retinopathy
| Article | Year |
|---|---|
[Aminoguanidine and other AGE inhibitors].
Topics: Amides; Animals; Arteriosclerosis; Cardiovascular Diseases; Cataract; Clinical Trials as Topic; Diabetes Mellitus; Diabetic Nephropathies; Diabetic Retinopathy; Disease Models, Animal; Drug Design; Glycation End Products, Advanced; Guanidines; Humans; Hydrazines; Hypoglycemic Agents; Thiadiazoles; Thiazoles; Thiazolidines | 2002 |
Aldose reductase inhibitors: a potential new class of agents for the pharmacological control of certain diabetic complications.
Topics: Aldehyde Reductase; Animals; Binding Sites; Blood Glucose; Cataract; Chemical Phenomena; Chemistry; Corneal Diseases; Diabetes Complications; Diabetes Mellitus; Diabetic Angiopathies; Diabetic Nephropathies; Diabetic Neuropathies; Diabetic Retinopathy; Disease Models, Animal; Fluorenes; Galactose; Humans; Hydantoins; Imidazoles; Imidazolidines; Models, Molecular; Naphthalenes; Phthalazines; Rhodanine; Sorbitol; Structure-Activity Relationship; Substrate Specificity; Sugar Alcohol Dehydrogenases; Thiazolidines; Tissue Distribution | 1985 |
1 trial(s) available for thiazolidines and Diabetic Retinopathy
| Article | Year |
|---|---|
Stratified analyses for selecting appropriate target patients with diabetic peripheral neuropathy for long-term treatment with an aldose reductase inhibitor, epalrestat.
Topics: Administration, Oral; Aged; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Diabetic Retinopathy; Enzyme Inhibitors; Female; Glycated Hemoglobin; Humans; Long-Term Care; Male; Middle Aged; Patient Selection; Proteinuria; Rhodanine; Thiazolidines; Treatment Outcome | 2008 |
9 other study(ies) available for thiazolidines and Diabetic Retinopathy
| Article | Year |
|---|---|
Effect of ranirestat, a new aldose reductase inhibitor, on diabetic retinopathy in SDT rats.
Topics: Administration, Oral; Aldehyde Reductase; Animals; Blood Glucose; Body Weight; Diabetic Retinopathy; Disease Models, Animal; Drug Administration Schedule; Enzyme Inhibitors; Glial Fibrillary Acidic Protein; Glycated Hemoglobin; Male; Neuroprotective Agents; Pyrazines; Rats; Rats, Sprague-Dawley; Retina; Rhodanine; Spiro Compounds; Thiazolidines; Time Factors | 2014 |
Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neurop
Topics: Aged; Aged, 80 and over; Aldehyde Reductase; Asian People; Blood Glucose; Cost-Benefit Analysis; Diabetic Neuropathies; Diabetic Retinopathy; Disease Progression; Enzyme Inhibitors; Female; Glycated Hemoglobin; Humans; Male; Middle Aged; Multivariate Analysis; Neural Conduction; Rhodanine; Severity of Illness Index; Thiazolidines; Time Factors; Treatment Outcome | 2012 |
Suppression of diabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kappaB pathway.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Animals; Benzamides; Blotting, Western; Cell Adhesion; Chemokine CCL2; Cyclohexanones; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Enzyme-Linked Immunosorbent Assay; Imidazoles; Intercellular Adhesion Molecule-1; Leukocytes; Male; Mice; Mice, Inbred C57BL; NF-kappa B; Pyridines; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Retinitis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tetrazoles; Thiazolidines; Valine; Valsartan; Vascular Endothelial Growth Factor A | 2007 |
Changes in erythrocyte sorbitol concentrations measured using an improved assay system in patients with diabetic complications and treated with aldose reductase inhibitor.
Topics: Adolescent; Adult; Aged; Aldehyde Reductase; Blood Glucose; Child; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diabetic Neuropathies; Diabetic Retinopathy; Enzyme Inhibitors; Erythrocytes; Female; Glycated Hemoglobin; Humans; Male; Middle Aged; Regression Analysis; Reproducibility of Results; Rhodanine; Sorbitol; Spectrophotometry; Thiazolidines | 1998 |
Effect of aldose reductase inhibitor on corneal epithelial barrier function in galactose-fed dogs.
Topics: Aldehyde Reductase; Animals; Diabetic Retinopathy; Diet; Dogs; Enzyme Inhibitors; Epithelium, Corneal; Fluorescence; Galactose; Male; Reference Values; Rhodanine; Thiazolidines | 1998 |
Epalrestat, an aldose reductase ihibitor, reduces the levels of Nepsilon-(carboxymethyl)lysine protein adducts and their precursors in erythrocytes from diabetic patients.
Topics: Aldehyde Reductase; Blood Glucose; Blood Proteins; Deoxyglucose; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Diabetic Retinopathy; Enzyme Inhibitors; Erythrocytes; Female; Glycated Hemoglobin; Glycation End Products, Advanced; Humans; Lysine; Male; Middle Aged; Reference Values; Rhodanine; Thiazolidines | 2000 |
[Diabetes mellitus and its complications in Japan. Pathogenesis and correspondence of diabetic retinopathy--approach from polyol metabolism].
Topics: Animals; Diabetic Retinopathy; Electroretinography; Humans; Male; Middle Aged; Polymers; Rats; Rats, Inbred Strains; Retina; Rhodanine; Thiazolidines | 1991 |
[Conservative therapy of diabetic eye disease].
Topics: Adult; Age Factors; Aged; Blood Glucose; Diabetic Retinopathy; Diet Therapy; Exercise Therapy; Female; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Polymers; Rhodanine; Sex Factors; Thiazolidines | 1991 |
[Experimentally induced diabetic retinal microangiopathy and polyol pathway. II. Effect of aldose reductase inhibitors on microangiopathy].
Topics: Aldehyde Reductase; Animals; Diabetic Retinopathy; Male; Rats; Rats, Inbred Strains; Rhodanine; Sugar Alcohol Dehydrogenases; Thiazoles; Thiazolidines | 1985 |